Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Tomorrow...Tomorrow...Prothena's options expire tomorrow
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(331)
•••
Comment by regardlesson Dec 30, 2020 10:20pm
160 Views
Post# 32201200

RE:RE:RE:RE:RE:RE:RE:Tomorrow...Tomorrow...Prothena's options expire tomorrow

RE:RE:RE:RE:RE:RE:RE:Tomorrow...Tomorrow...Prothena's options expire tomorrowChristi ... it's hear say only that we have other partners we are working on.. chiesi yes but as far as any other that is all hear say

dr rathjen said there may be deliver another deal or two by the end of this year .... well tomorrow is the end 

but it doesn't mean those presumed deals will be delivered at all In 2021 either 

hear say is all
we have and therefor prothema exercising again would be great for us ... at least they are that much farther than chiesi as far as using xb3 is concerned in the grand scheme of things 
they above anyone else would know how good our transport vector is 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities